Skip to main content

Animations

MJFF Publications

6061 - 6070 of 8808 Results
Title
Year
  • Year
  • 2024
  • 2023
  • 2017
  • 2017
  • 2015
  • 2022
  • 2022
  • 2012
  • 2019
  • 2021
  • Summary Details
    OPEN
    Title: The landscape of rare genetic variation associated with inflammatory bowel disease and Parkinson’s disease comorbidity
    Journal Name: Genome Medicine
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s13073-024-01335-2
    Citation Count: 11
  • Summary Details
    OPEN
    Title: Comparison of two protocols for the generation of iPSC-derived human astrocytes
    Journal Name: Biological Procedures Online
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s12575-023-00218-x
    Citation Count: 6
  • Summary Details
    OPEN
    Title: A randomized, double‐blind, placebo‐controlled trial of camicinal in Parkinson's disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/mds.27259
    Citation Count: 16
  • Summary Details
    OPEN
    Title: Heritability of hippocampal subfield volumes using a twin and non-twin siblings design
    Journal Name: Human Brain Mapping
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/hbm.23654
    Citation Count: 29
  • Summary Details
    OPEN
    Title: Fidelity of frequency and phase entrainment of circuit-level spike activity during DBS
    Journal Name: Journal of Neurophysiology
    Publisher: American Physiological Society
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1152/jn.00259.2015
    Citation Count: 47
  • Summary Details
    OPEN
    Title: LRRK2 dynamics analysis identifies allosteric control of the crosstalk between its catalytic domains
    Journal Name: PLOS Biology
    Publisher: Public Library of Science (PLoS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1371/journal.pbio.3001427
    Citation Count: 25
  • Summary Details
    RESTRICTED
    Title: Structure–Functional Selectivity Relationship Studies on A-86929 Analogs and Small Aryl Fragments toward the Discovery of Biased Dopamine D1 Receptor Agonists
    Journal Name: ACS Chemical Neuroscience
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1021/acschemneuro.2c00235
    Citation Count: 3
  • Summary Details
    OPEN
    Title: GSK2578215A; A potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor
    Journal Name: Bioorganic & Medicinal Chemistry Letters
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.bmcl.2012.06.104
    Citation Count: 149
  • Summary Details
    OPEN
    Title: Development of a Disease Progression Model for Leucine‐Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs
    Journal Name: Clinical Pharmacology & Therapeutics
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/cpt.1634
    Citation Count: 18
  • Summary Details
    OPEN
    Title: Correction: Data Sharing Goals for Nonprofit Funders of Clinical Trials
    Journal Name: Journal of Participatory Medicine
    Publisher: JMIR Publications Inc.
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.2196/31371
    Citation Count: 0
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.